In a pooled analysis of six clinical studies in adults with T1D, faster aspart administered via subcutaneous injection demonstrated an accelerated pharmacological profile compared with IAsp.21, 26 Faster aspart had an approximately 5‐minute earlier onset of appearance in the circulation, an approximately two‐fold higher early insulin exposure and an approximately 74% greater early glucose‐lowering effect within the first 30 minutes compared with IAsp.26 In addition, offset of exposure and glucose‐lowering effect occurred 12–14 minutes earlier with faster aspart than with IAsp. The gene discussed is INS; the disease is type 1 diabetes mellitus.